Moderna Wins EU Contract for RSV Vaccine Supply

Moderna has secured a contract with the European Commission to supply its RSV vaccine, mRESVIA, to six countries. The deal provides access to up to 24 million doses over four years for Austria, Denmark, Ireland, Luxembourg, Norway, and Portugal. The vaccine, authorized for adults in the EU, is designed to prevent serious respiratory disease caused by RSV, a leading cause of pneumonia and death in infants and older adults.

EU vaccine supply contract

• ▪The agreement provides access to up to 24 million doses of the vaccine over a period of up to four years
• ▪Moderna had a similar joint procurement framework agreement with the European Commission for its COVID-19 vaccines
• ▪The participating countries in the supply agreement are Austria, Denmark, Ireland, Luxembourg, Norway, and Portugal
• ▪Moderna secured a contract with the European Commission to supply its respiratory syncytial virus (RSV) vaccine to six European countries

mRESVIA vaccine specifications

• ▪Moderna's RSV vaccine, mRESVIA, is authorized in the European Union to prevent lower respiratory tract disease in adults
• ▪The mRESVIA vaccine will be supplied in a ready-to-use, single-dose pre-filled syringe to ease administration for healthcare professionals

RSV disease background

• ▪RSV is a leading cause of pneumonia and death in infants and older adults
• ▪Respiratory syncytial virus (RSV) is a common virus that causes seasonal infections similar to the flu

Moderna respiratory vaccine portfolio

• ▪Moderna's portfolio includes a combined influenza and COVID-19 vaccine that is authorized in Europe
• ▪Moderna has four approved mRNA vaccines for respiratory infections